UT-MD Anderson Cancer Center: ASH - Novel Combination Therapy Significantly Reduces Spleen Volume in Patients With Myelofibrosis
December 11, 2023
December 11, 2023
HOUSTON, Texas, Dec. 11 (TNSres) -- The University of Texas's MD Anderson Cancer Center issued the following news release:
* * *
MD Anderson-led Phase III trial nearly doubled number of patients with spleen size reduction
* * *
ABSTRACT: 620
Combining the JAK inhibitor ruxolitinib with the BCL-xL inhibitor navitoclax was twice as effective in reducing enlarged spleens - a major indicator of clinical improvement - compared with stan . . .
* * *
MD Anderson-led Phase III trial nearly doubled number of patients with spleen size reduction
* * *
ABSTRACT: 620
Combining the JAK inhibitor ruxolitinib with the BCL-xL inhibitor navitoclax was twice as effective in reducing enlarged spleens - a major indicator of clinical improvement - compared with stan . . .